Analyst Ratings For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Today, HC Wainwright raised its price target on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to $15.00 per share.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is Buy with a consensus target price of $13.00 per share, a potential 142.09% upside.
Some recent analyst ratings include
- 3/16/2018-Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) had its Buy rating reiterated by Seaport Global Securities with a $11.00 price target
- 2/8/2018-Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has coverage initiated with a Outperform ➝ Outperform rating and $9.00 price target
- 4/11/2017-Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) had its Outperform rating reiterated by FBR & Co
About Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Recent Trading Activity for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Shares of Aurinia Pharmaceuticals Inc closed the previous trading session at 5,37 −0,080 1,47 % with 5.64 shares trading hands.